Intersect ENT Inc. (XENT) is Trading Higher on Unusual Volume for January 01

Equities Staff  |

Intersect ENT Inc. (XENT) experienced unusually high volume on Jan. 01, as the stock gained 1.12% to a closing price of $22.50. The stock saw 449,458 shares trade hands over the course of the day on 3,111 trades. Given that the stock’s average daily volume over the last month has been 275,295 shares a day, this represents a pretty substantial spike over the norm.

Intersect ENT Inc. has a P/B ratio of 4.72. The stock has traded between $32.85 and $15.74 over the last 52-weeks, its 50-day SMA is now $19.73, and its 200-day SMA $24.54.

Intersect ENT Inc is a commercial stage drug-device company engaged in improving the life for patients with ear, nose and throat conditions.

Headquartered in Menlo Park, CA, Intersect ENT Inc. has 212 employees and is currently under the leadership of CEO Lisa E. Earnhardt.

For a complete fundamental analysis analysis of Intersect ENT Inc., check out’s Stock Valuation Analysis report for XENT. To see the latest independent stock recommendations from’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










Q BioMed CEO provides a Corporate Update

Denis Corin, CEO of Q BioMed Inc. ”Q“, a biomedical acceleration and development company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides a corporate update.

Emerging Growth

Global Cannabis

Global Cannabis Applications Corp is engaged in the design, acquire data and develop applications for smartphones and tablets. The company offer Citizen Green platform, an end to end infrastructure to…